Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare $(MHLW.SI)$ has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide $(CNP)$ action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。